POTE2 inhibitors are a chemical class that specifically targets and modulates the activity of the POTE2 protein. The POTE (Prostate, Ovary, Testis, and Embryo) gene family encodes a set of proteins that are mainly expressed in reproductive tissues, but they are also known to be expressed in other cell types. POTE2, as one member of this gene family, belongs to a group of proteins that exhibit significant sequence homology with actin and contain ankyrin repeat domains. These structural features suggest that POTE2 plays a role in cytoskeletal dynamics, cellular architecture, and possibly signal transduction. Inhibitors of POTE2 function by interacting with key domains of this protein, altering its ability to carry out its biological roles, particularly in processes involving cellular scaffolding and organization. Inhibitors may act either by directly binding to the protein or by affecting its regulatory pathways, leading to changes in cellular behavior, particularly in the reproductive tissues where POTE2 is primarily expressed.
From a chemical standpoint, POTE2 inhibitors may vary widely in their molecular structure, but they tend to share functional groups that enable high-affinity binding to the protein's active or regulatory sites. These inhibitors may possess aromatic rings, hydrophobic groups, and heteroatoms that allow them to form stable interactions, either via hydrogen bonds or hydrophobic interactions, with the POTE2 protein. Their specificity for POTE2 can be enhanced by optimizing molecular configurations that fit precisely into the unique pockets of the protein structure. Research into these inhibitors focuses on understanding the precise mechanisms by which they modulate the protein's activity, as well as the downstream cellular consequences of POTE2 inhibition, such as changes in cytoskeletal dynamics and protein-protein interactions. This chemical class is valuable for studying the biological role of POTE2 in non-clinical experimental models, offering insights into cell biology and protein regulation.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Fluorouracil | 51-21-8 | sc-29060 sc-29060A | 1 g 5 g | $36.00 $149.00 | 11 | |
5-Fluorouracil inhibits thymidylate synthase, a key enzyme in DNA synthesis, and may interfere with POTEE expression, potentially impacting cancer cell growth. | ||||||
Lapatinib | 231277-92-2 | sc-353658 | 100 mg | $412.00 | 32 | |
Lapatinib inhibits receptor tyrosine kinases, affecting downstream signaling pathways. Its interference with these pathways may lead to the inhibition of POTEE expression in cancer cells. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $47.00 $145.00 | 51 | |
Dasatinib is a kinase inhibitor, and it may interfere with signaling pathways involved in cancer cell proliferation, potentially impacting the expression of POTEE in cancer cells. | ||||||
Doxorubicin | 23214-92-8 | sc-280681 sc-280681A | 1 mg 5 mg | $173.00 $418.00 | 43 | |
Doxorubicin intercalates DNA, inhibits topoisomerase II, and generates free radicals. This compound's interference with DNA processes may lead to the inhibition of POTEE expression in cancer cells. | ||||||
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $25.00 $117.00 $209.00 | 27 | |
Imatinib inhibits BCR-ABL and other tyrosine kinases. By disrupting these signaling pathways, Imatinib may impact the expression of POTEE in cancer cells. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $56.00 $260.00 $416.00 | 129 | |
Sorafenib is a kinase inhibitor that affects the RAF/MEK/ERK pathway. Its interference with this pathway may lead to the inhibition of POTEE expression in cancer cells. | ||||||
Taxol | 33069-62-4 | sc-201439D sc-201439 sc-201439A sc-201439E sc-201439B sc-201439C | 1 mg 5 mg 25 mg 100 mg 250 mg 1 g | $40.00 $73.00 $217.00 $242.00 $724.00 $1196.00 | 39 | |
Paclitaxel stabilizes microtubules and interferes with their breakdown during cell division. This interference may impact the expression of POTEE in cancer cells. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $132.00 $1064.00 | 115 | |
Bortezomib inhibits the 26S proteasome, affecting the degradation of specific proteins. Its impact on protein degradation may lead to the inhibition of POTEE expression in cancer cells. | ||||||
Tamoxifen | 10540-29-1 | sc-208414 | 2.5 g | $256.00 | 18 | |
Tamoxifen is a selective estrogen receptor modulator. Its interference with estrogen signaling may impact the expression of POTEE, which is found to be expressed in hormone-related cancers. | ||||||
Cisplatin | 15663-27-1 | sc-200896 sc-200896A | 100 mg 500 mg | $76.00 $216.00 | 101 | |
Cisplatin forms DNA cross-links, leading to inhibition of DNA replication and transcription. This interference may impact the expression of POTEE in cancer cells. | ||||||